2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 3000
No.37
“The Cyclophilin Inhibitor, CPI-431-32, is a Hepatitis B Oral Drug Candidate with Antiviral and Antifibrotic Activities” Ciclofilin Pharmaceuticals Inc.
No.36
“Empagliflozin (an SGLT2 inhibitor), alone or in combination with linagliptin (a DPP-4 inhibitor), prevents steatohepatitis in a novel mouse model of non-alcoholic steatohepatitis and diabetes” Dokkyo Medical University
No.35
“Anti-Fibrotic Effect of Autotaxin and LPA1R Antagonists in a Rodent Model of NASH” Bristol-Myers Squibb Company
No.34
“Sitagliptin, a Dipeptidyl Peptidase 4 inhibitor, Suppressed Tumor Progression with Down-regulation of Nrf Nuclear Expression in a Mouse Model of Non-alcoholic Steatohepatitis-related Hepatocellular Carcinoma” Kurume University School of Medicine
No.33
“Reduction of Hepatic 27-Hydroxycholesterol in Steatohepatitis Model Mice with Insulin Resistance” Tokyo Medical University Ibaraki Medical Center
No.32
“Disturbance of regulatory T cells, MDSCs and NK cells is involved in NASH and mouse model of NASH” Tohoku University Hospital.
No.31
“Mechanism of Action of the Anti-NASH effects of Solithromycin in a Predictive NASH HCC Mouse Model” Cempra Pharmaceuticals, Inc.
No.30
“Effects of Sitagliptin, a Dipeptidyl Peptidase 4 Inhibitor, on Tumor Progression and p62/SQSTM1 Subcellular Localization in a Mouse Model of Non-Alcoholic Steatohepatitis-Related Hepatocellular Carcinoma” Kurume University
No.29
DGAT2 Inhibition Prevents NAFLD and Fibrosis in the STAM™ Mouse Model of NASH“ Pfizer Inc.
No.28
“Oxidized-Phospholipid Small Molecule Inhibits Non-Alcoholic Steatohepatitis (NASH) and Liver Fibrosis“ Vascular Biogenics Ltd